Jump to content

GABAA receptor positive allosteric modulator

From Wikipedia, the free encyclopedia
Fig 1. Chemical structure of gamma-aminobutyric acid or GABA
Fig 2. Schematic diagram of a GABAA receptor protein ((α1)2(β2)2(γ2)) which illustrates the five combined subunits that form the protein, the chloride (Cl-) ion channel pore, the two GABA active binding sites at the α1 and β2 interfaces, and the benzodiazepine (BZD) allosteric binding site at the α1 and γ2 interface.

In pharmacology, GABAA receptor positive allosteric modulators, also known as GABAkines or GABAA receptor potentiators,[1] are positive allosteric modulator (PAM) molecules that increase the activity of the GABAA receptor protein in the vertebrate central nervous system.

GABA is a major inhibitory neurotransmitter in the central nervous system. Upon binding, it triggers the GABAA receptor to open its chloride channel to allow chloride ions into the neuron, making the cell hyperpolarized and less likely to fire. GABAA PAMs increase the effect of GABA by making the channel open more frequently or for longer periods. However, they have no effect if GABA or another agonist is not present.

Unlike GABAA receptor agonists, GABAA PAMs do not bind at the same active site as the γ-aminobutyric acid (GABA) neurotransmitter molecule: they affect the receptor by binding at a different site on the protein. This is called allosteric modulation.

In psychopharmacology, GABAA receptor PAMs used as drugs have mainly sedative and anxiolytic effects. Examples of GABAA PAMs include ethanol, benzodiazepines such as diazepam (Valium) and alprazolam (Xanax), Z-drugs such as zolpidem (Ambien) and the barbiturate drugs.

History

[edit]

The GABAA receptors have historically been a target of drug treatment research. The earliest compounds were ionic compounds, such as bromide.

Barbiturates

[edit]

In 1903, the first psychoactive derivative of barbituric acid was synthesized and marketed for headaches. Within 30 years, many other barbiturates were developed and found use as sedatives, sleep aids and general anesthetics. Although barbiturates fell out of favor, they continue to serve as a short-acting anesthetic and anti-epileptic drugs.

Benzodiazepines

[edit]

Benzodiazepines were discovered in 1955 and largely replaced the barbiturates because of their larger therapeutic index.[2] At first benzodiazepines were considered to be safe and efficient minor tranquilizers but then were criticized for their dependence producing effects. Several efficient benzodiazepines offer choices about dosage form, length of action, metabolic interaction and safety.

Benzodiazepines function by binding to the benzodiazepine site on most, but not all, GABAA receptors. GABAA modulation by benzodiazepine site agonists is self-limiting. The channel conductance is not higher in the presence of benzodiazepine and GABA than the conductance with the presence of only high GABA concentrations. Additionally, in the absence of GABA the presence of benzodiazepines alone does not open the chloride channel.[3]

Neurosteroids

[edit]

Certain metabolites of progesterone and deoxycorticosterone are potent and selective positive allosteric modulators of the γ-aminobutyric acid type A (GABAA) receptor.[4] Hans Selye demonstrated in 1940 that certain pregnane steroids could cause both anesthesia and sedation,[5] but 40 years later the molecular mechanism emerged to explain their depressant effect. In a rat brain slice preparation, the synthetic steroidal anesthetic alphaxalone (5α-pregnan-3α-ol-11,20 dione) enhanced both stimulus-evoked inhibition and the effects of exogenously applied muscimol, which is a GABAA selective agonist.[6]

Receptor

[edit]
See also: GABA receptor
Fig 3. Binding sites of different therapeutic chemical groups on a GABAA receptor

The GABAA receptors are made up of subunits which form a receptor complex. Humans have 19 receptor subunits and are classified into α (1–6), β (1–3), γ (1–3), δ, ε, π, θ, and ρ (1−3). The function of the receptor is different according to how the pentameric complex is put together. The most common complex that includes around 40% of the GABAA receptors is the α1β2γ2 combination. The expression of the subunits can be very different depending on brain region.[7] The combination of the subunits influences how the receptor acts. For example, if the α1 and β2 subunits are expressed together they have high sensitivity to GABA, but low channel conductance. But if the γ2 is expressed with α1 and β2 the sensitivity is low and channel conductance is high.[8] γ2 subunit has to be present for high affinity binding of benzodiazepine. Little is known about where different complexes are located in the brain, complicating drug discovery.[7] For example, the binding site of neurosteroids in the GABAA receptor is not known[9] and barbiturates bind at a beta subunit that is distinct from the benzodiazepine binding site.

Available agents

[edit]

Applications

[edit]

Barbiturates

[edit]

Barbiturates' precise action sites have not yet been defined. The second and third transmembrane domains of the β subunit appear to be critical; binding may involve a pocket formed by β-subunit methionine 286 as well as α-subunit methionine 236.[13]

Insomnia

[edit]

Barbiturates were introduced as hypnotics for patients with schizophrenia. It induced a state of deep and prolonged sleep. But this was not used for long because of adverse side effects.[2]

Anticonvulsant

[edit]

Phenobarbital was the first truly effective drug against epilepsy. It was discovered by accident when given to epileptic patients to help them sleep. The positive side effects were anticonvulsant properties that reduced seizure number and intensity.[2]

Sedation

[edit]

Pentobarbital is used as a hypnotic when analgesia is not required. It´s often used in CT imaging when sedation is needed. It is efficient, safe and the recovery time is short.[14] In 2013 the barbiturates phenobarbital and butabarbital are still used as sedatives in certain cases as well as to antagonize the effects of drugs as ephedrine and theophylline. Phenobarbital is used in cases of drug withdrawal syndromes. It is used as normal and emergency treatment in some cases of epilepsy.[2]

Fig 4. GABAergic synapse. The synaptic anchoring protein Gephyrin is indirectly linked to the GABAA receptors.

Benzodiazepine

[edit]

Synaptic action of benzodiazepines: GABAA receptors located at synapses are activated when they are exposed to high concentration of GABA. Benzodiazepines enhance the receptor affinity for GABA by increasing the decay of spontaneous miniature inhibitory postsynaptic currents (mIPSC).[15][16]

Analgesia

[edit]

Sedative actions of benzodiazepines limit their usefulness as analgesic agents and they are therefore generally not considered to be appropriate. This limitation can be bypassed by intrathecal administration. GABAA receptors in the periaqueductal gray are pro-nociceptive at supraspinal sites while GABAA that are found in the spinal cord are anti-hyperalgesic. Spinal α2 and α3 containing GABAA receptors are responsible for the anti-hyperalgesic action of intrathecal diazepam. This was shown when the anti-hyperalgesic action was reduced when administered in α2 and α3 mice in inflammatory pain and in neuropathic pain. Additionally, studies in α5 mice showed that the spinal α5-containing GABAA receptor has a minor role in inflammatory pain. An α2, α3 and/or α5 selective positive allosteric agonist, like L-838,417 for example, might be useful as an analgesic drug against inflammatory or neuropathic pain.[3] Further studies in animal neuropathic pain models have shown that stabilizing the potassium chloride cotransporter 2 (KCC2) at neuronal membranes could not only potentiate the L-838,417-induced analgesia but also rescue its analgesic potential at high doses, revealing a novel strategy for analgesia in pathological pain, by combined targeting of the appropriate GABAA receptor subtypes (i.e. α2, α3) and restoring Cl− homeostasis.[17]

Schizophrenia

[edit]

Benzodiazepines are used as a supporting treatment in patients with schizophrenia.[3]

Depression

[edit]

A GABAergic hypothesis for depression has been proposed which places the GABA system in a central role in the pathophysiology of depression. Clinical studies have shown that alprazolam and adinazolam have antidepressant activities in patients with major depressive disorder. Unfortunately, it is not known which receptor subtype is responsible for the antidepressant activities.

Studies in y2 knockout mice have shown that they display increased anxiety and depressive-like symptoms in despair-based tests. The mice also had increased corticosterone concentration, which is a symptom in major depression in humans. The y2 subunit is associated with α1-α6 subunits, which are all known α subunits, so these studies do not show which of the α subunits are related to the depressive-like symptoms. Other studies with α2 knockout mice have displayed increased anxiety and depression-like symptoms in conflict-based feeding tests. The fact that anxiety and depression are often linked seems to indicate that the α2 subunit might be a valid target for a GABAA antidepressant.[3]

Stroke

[edit]

Preclinical studies have shown that benzodiazepines can be effective in reducing the effect of strokes for up to three days after the drug has been administered.[3]

Neurosteroids

[edit]

Neurosteroids can act as allosteric modulators of neurotransmitter receptors, such as the GABAA,[18][19][20][21] NMDA,[22] and sigma receptors.[23] The neurosteroid progesterone (PROG) that activates progesterone receptors expressed in peripheral and central glial cells.[24][25][26][27] Additionally it has been surmised that the 3α-hydroxy ring A-reduced pregnane steroids allopregnanolone and tetrahydrodeoxycorticosterone increase the GABA-mediated chloride currents while pregnenolone sulfate and dehydroepiandrosterone (DHEA) sulfate on the other hand display antagonistic properties at the GABAA receptors.

Synthesis

[edit]

Barbituric acid

[edit]
Fig 5. Original synthesis of Barbituric acid
Fig 6. Current synthesis of barbituric acid

Barbituric acid is the parent compound of barbiturate drugs although barbituric acid itself is not pharmacologically active. Barbiturates were synthesized in 1864 by Adolf von Baeyer by combining urea and malonic acid (Figure 5). A synthesis process was later developed and perfected by French chemist Edouard Grimaux in 1879, making possible the subsequent widespread development of barbiturate derivatives.[28] Malonic acid was later replaced by diethyl malonate, as using the ester avoids the need to deal with the acidity of the carboxylic acid and its unreactive carboxylate (see figure 6). Barbituric acid can form a large variety of barbiturate drugs by using the Knoevenagel condensation reaction.[29]

Fig 7. Synthesis and discovery of chlordiazepoxide

Benzodiazepines

[edit]

The structure that the first benzodiazepine is based on was discovered by Leo H. Sternbach. He thought the compound had a heptoxdiazine structure (Figure 7) but it was later determined to be a quinazoline-3-oxide. Possible drug candidates were then synthesized from that compound and screened for activity. One of these compounds was active, chlordiazepoxide. It was marketed in 1960 and became the first benzodiazepine drug.[30]

Biosynthesis of neurosteroids

[edit]

Neurosteroids are synthesized in the central nervous system (CNS) and the peripheral nervous system (PNS) from cholesterol and steroidal precursors that are imported from the peripheral sources. These sources include 3β-hydroxy-Δ5 derivatives, such as pregnenolone (PREG) and dehydroepiandrosterone (DHEA), their sulfates, and reduced metabolites such as the tetrahydro derivative of progesterone 3α-hydroxy-5α-pregnane-20-one (3α,5α-THPROG). After the local synthesis or from metabolism of adrenal of gonadal steroids many neurosteroids accumulate in the brain.[31][32]

Structure-activity relationship

[edit]

Barbiturates

[edit]
Fig 8. R-group position of Barbiturates

Barbiturates have special uses and are organized into 4 classes: ultrashort-, short-, intermediate- and long-acting. Empirically SARs of barbiturants are based on thousands of (animal) tested compounds. They have shown that R and R´ may not be H in position 5 (see figure 8). Also, position 5 confer sedative-hypnotic properties.[14] Generally alkyl branching in position 5 means less lipid solubility and less activity. Unsaturation show less activity in position 5 and alicyclic and aromatic rings show less potency. Polar substituents (-NH2, -OH, -COOH) will decrease lipid solubility but it will also eliminate activity. R´´ in position 1 is usually, H but CH3 in that position yields less lipid solubility and duration. Exchanging S for O atom in position 2 produces thiobarbiturates, which are more lipid-soluble than the oxybarbiturates. In general, the more lipid-soluble the barbiturate, the more rapid its onset, the shorter its duration and the greater the degree of hypnotic activity. Barbiturates showed some hydrolytic problems in regard to formulation of liquid dosage forms. The difficulty is -OH catalyzed degration of the ureide rings but that can be fixed if the pH is 6 in the formulation. S(-) form of barbiturate have shown more depressant activity while the R( ) isomers have an excitatory effect.[33]

Benzodiazepines

[edit]
Fig 9. Common R group positions of Benzodiazepines

According to research performed by Maddalena et al., using artificial neural networks, position 7 has the most effect on receptor affinity. When the active group in position 7 is made more lipophilic and the electronic charge is increased the receptor affinity increases. In the same study position 2´ was found to be the second-most important in affecting the affinity, but the group in that position needs to be electrophilic to have an effect. Positions 3, 6’ and 8 are of less importance.[34] Changes to 6, 8, 9 or 4´ decrease activity. If the group in position 1 is changed to N-alkyl, haloalkyl, alkynyl and small cycle or aminoalkyl the activity is increased. Position 3 hydroxylation can cause rapid conjugation and decrease duration and potency, which can be clinically useful.[34]

Fig 10. Different R-group analogs for neurosteroids. Groups 1–4 and 10 have significant therapeutic value.

Neurosteroids

[edit]

In the mid 1980s, the neuroactive steroids 3α,5α-tetrahydroprogesterone or allopregnanolone (3α,5α-THP) and 3α,5α-tetrahydrodeoxycorticosterone (3α,5α-THDOC) were shown to modulate neuronal excitability via their interaction with GABAA receptors. The steroids 3α,5α-THP and 3α,5α-THDOC were able to enhance the GABA-elicited Cl− current.[18] In addition, these steroids might enhance the binding of muscimol and benzodiazepines to GABAA receptors.[35] Structure- activity studies (SAR) showed that the 3alpha-OH group is essential for the anesthetic actions of these steroids,[36] they also have an optimally-placed hydrogen bond accepting group on the β face of the steroid at the C-17 position. The four steroid rings form a rigid framework for positioning these hydrogen groups in three-dimensional space.[37] Analogues 5 and 6 (Figure 10) are weak modulators of GABAA receptor function because the flexible side chains in these analogues do not have the conformations required for high biological activity.[38]

See also

[edit]

References

[edit]
  1. ^ Cerne R, Lippa A, Poe MM, Smith JL, Jin X, Ping X, Golani LK, Cook JM, Witkin JM (June 2022). "GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors". Pharmacol Ther. 234: 108035. doi:10.1016/j.pharmthera.2021.108035. PMC 9787737. PMID 34793859.
  2. ^ a b c d López-Muñoz F, Ucha-Udabe R, Alamo C (Dec 2005). "The history of barbiturates a century after their clinical introduction". Neuropsychiatric Disease and Treatment. 1 (4): 329–43. PMC 2424120. PMID 18568113.
  3. ^ a b c d e Rudolph U, Knoflach F (Sep 2011). "Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes". Nature Reviews. Drug Discovery. 10 (9): 685–97. doi:10.1038/nrd3502. PMC 3375401. PMID 21799515.
  4. ^ Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA (Sep 2003). "Neurosteroid modulation of GABAA receptors". Progress in Neurobiology. 71 (1): 67–80. doi:10.1016/j.pneurobio.2003.09.001. PMID 14611869. S2CID 11878482.
  5. ^ Selye H (1 January 1941). "Anesthetic Effect of Steroid Hormones". Experimental Biology and Medicine. 46 (1): 116–121. doi:10.3181/00379727-46-11907. S2CID 87160217.
  6. ^ Harrison NL, Simmonds MA (December 1984). "Modulation of the GABA receptor complex by a steroid anaesthetic". Brain Research. 323 (2): 287–92. doi:10.1016/0006-8993(84)90299-3. PMID 6098342. S2CID 43910919.
  7. ^ a b Egawa K, Fukuda A (2013). "Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models". Frontiers in Neural Circuits. 7: 170. doi:10.3389/fncir.2013.00170. PMC 3807051. PMID 24167475.
  8. ^ Günther U, Benson J, Benke D, Fritschy JM, Reyes G, Knoflach F, Crestani F, Aguzzi A, Arigoni M, Lang Y (Aug 1995). "Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type A receptors". Proceedings of the National Academy of Sciences of the United States of America. 92 (17): 7749–53. Bibcode:1995PNAS...92.7749G. doi:10.1073/pnas.92.17.7749. PMC 41223. PMID 7644489.
  9. ^ Hosie AM, Wilkins ME, Smart TG (Oct 2007). "Neurosteroid binding sites on GABA(A) receptors". Pharmacology & Therapeutics. 116 (1): 7–19. doi:10.1016/j.pharmthera.2007.03.011. PMID 17560657.
  10. ^ Castagna, Rossella; Maleeva, Galyna; Pirovano, Deborah; Matera, Carlo; Gorostiza, Pau (2022-08-31). "Donor–Acceptor Stenhouse Adduct Displaying Reversible Photoswitching in Water and Neuronal Activity". Journal of the American Chemical Society. 144 (34): 15595–15602. doi:10.1021/jacs.2c04920. hdl:2445/188733. ISSN 0002-7863.
  11. ^ Ozawa, Masaki; Nakada, Yukie; Sugimachi, Keiko; Yabuuchi, Fumie; Akai, Tetsuo; Mizuta, Eiji; Kuno, Sadako; Yamaguchi, Motonori (1994-01-01). "Pharmacological Characterization of the Novel Anxiolytic β-Carboline Abecarnil in Rodents and Primates". Japanese Journal of Pharmacology. 64 (3): 179–188. doi:10.1254/jjp.64.179. ISSN 0021-5198.
  12. ^ Maleeva, Galyna; Nin-Hill, Alba; Wirth, Ulrike; Rustler, Karin; Ranucci, Matteo; Opar, Ekin; Rovira, Carme; Bregestovski, Piotr; Zeilhofer, Hanns Ulrich; König, Burkhard; Alfonso-Prieto, Mercedes; Gorostiza, Pau (2024-10-09). "Light-Activated Agonist-Potentiator of GABA A Receptors for Reversible Neuroinhibition in Wildtype Mice". Journal of the American Chemical Society. doi:10.1021/jacs.4c08446. ISSN 0002-7863. PMC 11503767.
  13. ^ Löscher W, Rogawski MA (Dec 2012). "How theories evolved concerning the mechanism of action of barbiturates". Epilepsia. 53 (Suppl 8): 12–25. doi:10.1111/epi.12025. PMID 23205959. S2CID 4675696.
  14. ^ a b Moro-Sutherland DM (September 2000). "Barbiturates". Clinical Pediatric Emergency Medicine. 1 (4): 276–280. doi:10.1016/S1522-8401(00)90040-5.
  15. ^ Möhler H, Fritschy JM, Rudolph U (Jan 2002). "A new benzodiazepine pharmacology". The Journal of Pharmacology and Experimental Therapeutics. 300 (1): 2–8. doi:10.1124/jpet.300.1.2. PMID 11752090. S2CID 24519126.
  16. ^ Perrais D, Ropert N (Jan 1999). "Effect of zolpidem on miniature IPSCs and occupancy of postsynaptic GABAA receptors in central synapses". The Journal of Neuroscience. 19 (2): 578–88. doi:10.1523/JNEUROSCI.19-02-00578.1999. PMC 6782193. PMID 9880578.
  17. ^ Lorenzo LE, Godin AG, Ferrini F, Bachand K, Plasencia-Fernandez I, Labrecque S, Girard AA, Boudreau D, Kianicka I, Gagnon M, Doyon N, Ribeiro-da-Silva A, De Koninck Y (2020). "Enhancing neuronal chloride extrusion rescues α2/α3 GABAA-mediated analgesia in neuropathic pain". Nature Communications. 11 (1): 869–92. Bibcode:2020NatCo..11..869L. doi:10.1038/s41467-019-14154-6. PMC 7018745. PMID 32054836.
  18. ^ a b Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (May 1986). "Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor". Science. 232 (4753): 1004–7. doi:10.1126/science.2422758. PMID 2422758.
  19. ^ Herd MB, Belelli D, Lambert JJ (Oct 2007). "Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors". Pharmacology & Therapeutics. 116 (1): 20–34. doi:10.1016/j.pharmthera.2007.03.007. PMID 17531325.
  20. ^ Hosie AM, Wilkins ME, da Silva HM, Smart TG (Nov 2006). "Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites". Nature. 444 (7118): 486–9. Bibcode:2006Natur.444..486H. doi:10.1038/nature05324. PMID 17108970. S2CID 4382394.
  21. ^ Puia G, Santi MR, Vicini S, Pritchett DB, Purdy RH, Paul SM, Seeburg PH, Costa E (May 1990). "Neurosteroids act on recombinant human GABAA receptors". Neuron. 4 (5): 759–65. doi:10.1016/0896-6273(90)90202-Q. PMID 2160838. S2CID 12626366.
  22. ^ Wu FS, Gibbs TT, Farb DH (Sep 1991). "Pregnenolone sulfate: a positive allosteric modulator at the N-methyl-D-aspartate receptor" (abstract). Molecular Pharmacology. 40 (3): 333–6. PMID 1654510.
  23. ^ Maurice T, Junien JL, Privat A (Feb 1997). "Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via sigma 1-receptors". Behavioural Brain Research. 83 (1–2): 159–64. doi:10.1016/S0166-4328(97)86061-5. PMID 9062676. S2CID 3979800.
  24. ^ Baulieu EE (1997). "Neurosteroids: of the nervous system, by the nervous system, for the nervous system". Recent Progress in Hormone Research. 52: 1–32. PMID 9238846.
  25. ^ Rupprecht R, Reul JM, Trapp T, van Steensel B, Wetzel C, Damm K, Zieglgänsberger W, Holsboer F (Sep 1993). "Progesterone receptor-mediated effects of neuroactive steroids". Neuron. 11 (3): 523–30. doi:10.1016/0896-6273(93)90156-L. PMID 8398145. S2CID 11205767.
  26. ^ Jung-Testas I, Do Thi A, Koenig H, Désarnaud F, Shazand K, Schumacher M, Baulieu EE (1999). "Progesterone as a neurosteroid: synthesis and actions in rat glial cells". The Journal of Steroid Biochemistry and Molecular Biology. 69 (1–6): 97–107. doi:10.1016/S0960-0760(98)00149-6. PMID 10418983. S2CID 10662223.
  27. ^ Belelli D, Lambert JJ (Jul 2005). "Neurosteroids: endogenous regulators of the GABA(A) receptor". Nature Reviews. Neuroscience. 6 (7): 565–75. doi:10.1038/nrn1703. PMID 15986366. S2CID 12596378.
  28. ^ Carter, MK (1951). "The history of barbituric acid". J Chem Educ. 28 (10): 525–8. Bibcode:1951JChEd..28..524C. doi:10.1021/ed028p524.
  29. ^ Deb ML, Bhuyan, Pulak J. (September 2005). "Uncatalysed Knoevenagel condensation in aqueous medium at room temperature". Tetrahedron Letters. 46 (38): 6453–6456. doi:10.1016/j.tetlet.2005.07.111.
  30. ^ Gringauz A (1997). Medicinal Chemistry How drugs act and why. United States of America: WILEY-VCH. pp. 578–579. ISBN 0-471-18545-0.
  31. ^ Agís-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, Guidotti A (Sep 2006). "Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis". Proceedings of the National Academy of Sciences of the United States of America. 103 (39): 14602–7. Bibcode:2006PNAS..10314602A. doi:10.1073/pnas.0606544103. PMC 1600006. PMID 16984997.
  32. ^ Mellon SH, Griffin LD (2002). "Neurosteroids: biochemistry and clinical significance". Trends in Endocrinology and Metabolism. 13 (1): 35–43. doi:10.1016/S1043-2760(01)00503-3. PMID 11750861. S2CID 11605131.
  33. ^ Gringauz A (1997). Medicinal Chemistry How drugs act and why. United States of America: Wiley-VCH. pp. 572–574. ISBN 0-471-18545-0.
  34. ^ a b Maddalena DJ, Johnston GA (Feb 1995). "Prediction of receptor properties and binding affinity of ligands to benzodiazepine/GABAA receptors using artificial neural networks". Journal of Medicinal Chemistry. 38 (4): 715–24. doi:10.1021/jm00004a017. PMID 7861419.
  35. ^ Paul SM, Purdy RH (Mar 1992). "Neuroactive steroids". FASEB Journal. 6 (6): 2311–22. doi:10.1096/fasebj.6.6.1347506. PMID 1347506. S2CID 221753076.
  36. ^ Covey DF, Han M, Kumar AS, de La Cruz MA, Meadows ES, Hu Y, Tonnies A, Nathan D, Coleman M, Benz A, Evers AS, Zorumski CF, Mennerick S (Aug 2000). "Neurosteroid analogues. 8. Structure-activity studies of N-acylated 17a-aza-D-homosteroid analogues of the anesthetic steroids (3alpha, 5alpha)- and (3alpha,5beta)-3-hydroxypregnan-20-one". Journal of Medicinal Chemistry. 43 (17): 3201–4. doi:10.1021/jm0002477. PMID 10966737.
  37. ^ Covey DF, Evers AS, Mennerick S, Zorumski CF, Purdy RH (Nov 2001). "Recent developments in structure-activity relationships for steroid modulators of GABA(A) receptors". Brain Research. Brain Research Reviews. 37 (1–3): 91–7. doi:10.1016/S0165-0173(01)00126-6. PMID 11744077. S2CID 35297361.
  38. ^ Covey DF, Hu Y, Bouley MG, Holland KD, Rodgers-Neame NT, Isenberg KE, Zorumski CF (Mar 1993). "Modulation of GABAA receptor function by benz[e]indenes and phenanthrenes". Journal of Medicinal Chemistry. 36 (5): 627–30. doi:10.1021/jm00057a012. PMID 8388475.

Further reading

[edit]
  • Faizi M, Dabirian S, Tajali H, Ahmadi F, Zavareh ER, Shahhosseini S, Tabatabai SA (Feb 2015). "Novel agonists of benzodiazepine receptors: design, synthesis, binding assay and pharmacological evaluation of 1,2,4-triazolo[1,5-a]pyrimidinone and 3-amino-1,2,4-triazole derivatives". Bioorganic & Medicinal Chemistry. 23 (3): 480–7. doi:10.1016/j.bmc.2014.12.016. PMID 25564376.
Retrieved from "https://en.wikipedia.org/w/index.php?title=GABAA_receptor_positive_allosteric_modulator&oldid=1255835497"